Angle jumps again after pay out
Medical technology firm Angle saw its shares jump for a second day in a row after it received cash due from the sale of its portfolio company Acoylte Biomedica.
Medical technology firm Angle saw its shares jump for a second day in a row after it received cash due from the sale of its portfolio company Acoylte Biomedica.
The 2007 sale led to a legal case over an earn-out provision, which saw former Acolyte shareholder, Porton Capital, take the buyer, 3M, to court.
Angle said that following Porton's victory it had received $286,226 - around £178,000 - which would be used to support working capital requirements.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company's founder and Chief Executive, Andrew Newland, said a strategy of observing the third party action against the purchaser, rather than participating in litigation, meant Angle had avoided substantial legal costs.
The news pushed shares were up 15% in early trading, which followed a 90% leap on Monday after the company announced a major breakthrough in its cancer diagnostic product Parsotix.
MM
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
UK-US trade deal announced: US cuts tariffs on UK car imports to 10%
Keir Starmer and Donald Trump have announced a UK-US trade deal, but the US president has refused to lift baseline tariffs on most UK goods. What does it mean for the UK?
-
How to use mid-caps to diversify from the US
Medium sized companies are overlooked by investors but could offer an attractive ‘sweet spot’. We consider the case for mid-caps amid market volatility.